Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?

about

New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil.

P2860

Q38712500-EC2733BC-EDFE-4257-8BFB-B9C88B6A62EB Q55496629-165700CF-A286-43E3-B10F-4A35740DE7A6

P2860

Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?

Item

http://www.wikidata.org/entity/Q38570681

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cost-Effectiveness Modeling in ...... und with Non-Healthcare Costs?

@en

type

Item

label

Cost-Effectiveness Modeling in ...... und with Non-Healthcare Costs?

@en

prefLabel

Cost-Effectiveness Modeling in ...... und with Non-Healthcare Costs?

@en

P1476

Cost-Effectiveness Modeling in ...... und with Non-Healthcare Costs?

@en

P2093

Francesca Ghislandi

http://www.w3.org/2001/XMLSchema#string

Livio Garattini

http://www.w3.org/2001/XMLSchema#string

Milene Rangel Da Costa

http://www.w3.org/2001/XMLSchema#string

P2860

Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

Multiple sclerosis

Incidence and prevalence of multiple sclerosis in Europe: a systematic review

Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.

Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.

Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.

Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.

Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.

A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.

P2888

s40273-015-0322-7

P304

1241-1244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-015-0322-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281169128

http://www.w3.org/2001/XMLSchema#string

P698

26293887

http://www.w3.org/2001/XMLSchema#string

Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?

about

P2860

P2860

Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698